Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU8KTO)

Drug Name
PP121 Drug Info
Synonyms PP-121; PP 121
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
24905142
ChEBI ID
CHEBI:50915
CAS Number
CAS 1092788-83-4
TTD Drug ID
DMU8KTO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting PI3-kinase beta (PIK3CB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Buparlisib DM1WEHC Breast cancer 2C60-2C65 Phase 3 [2]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [3]
PA-799 DMLSYJQ Colorectal cancer 2B91.Z Phase 1/2 [4]
AZD8186 DMWYF1H Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
GSK2636771 DMCBGLW Prostate cancer 2C82.0 Phase 1 [6]
BAY 1082439 DMLRGX1 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
AZD6482 DMVP4E5 Thrombosis DB61-GB90 Terminated [8]
PIK-75 DM9BQTX Discovery agent N.A. Investigative [9]
KU-0060648 DMQWS6U Discovery agent N.A. Investigative [10]
PI-3065 DMCQUWI Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Hematopoietic cell kinase (HCK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BK3 DM6YQO3 N. A. N. A. Patented [12]
Doramapimod DM6BU7N Inflammatory bowel disease DD72 Patented [13]
3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine DM0DYAU N. A. N. A. Patented [12]
Unii-I92MU0V408 DMUD7H8 N. A. N. A. Patented [13]
US8933228, 3 DMPNCOL N. A. N. A. Patented [13]
SB19065 DM2MQD0 N. A. N. A. Patented [14]
US9108950, 1 DMPT2ZS N. A. N. A. Patented [15]
US8933228, Ref 2 DMKEX51 N. A. N. A. Patented [16]
BK7 DMQD4X2 N. A. N. A. Patented [12]
PMID15546730C2 DMOPUIH Discovery agent N.A. Investigative [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [18]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [19]
Olaratumab DMNYOIX Soft tissue sarcoma 2B57 Approved [20]
Avapritinib DMK2GZX Gastrointestinal stromal tumour 2B5B Approved [21]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [22]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [23]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [24]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [25]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [26]
MEDI-575 DMI9WVM Glioblastoma multiforme 2A00.0 Phase 2 [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Epidermal growth factor receptor (EGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [28]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [29]
Gefitinib DM15F0X Solid tumour/cancer 2A00-2F9Z Approved [30]
Erlotinib DMCMBHA Non-small-cell lung cancer 2C25.Y Approved [31]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [32]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [33]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [34]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [35]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [33]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Serine/threonine-protein kinase mTOR (mTOR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sirolimus DMGW1ID Multiple myeloma 2A83 Approved [37]
Temsirolimus DMS104F Renal cell carcinoma 2C90 Approved [38]
PF-04449913 DMSB068 Chronic myelomonocytic leukaemia 2A40 Approved [39]
Everolimus DM8X2EH Renal cell carcinoma 2C90 Approved [40]
Novolimus DM6ZPLQ Artery stenosis BD52 Approved [41]
Zotarolimus DMRMCXW Solid tumour/cancer 2A00-2F9Z Approved [42]
Ridaforolimus DMLHEU7 Sarcoma 2A60-2C35 Phase 3 [43]
Azd2014 DMOEARH Solid tumour/cancer 2A00-2F9Z Phase 2 [44]
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [45]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [46]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [47]
Regorafenib DMHSY1I Metastatic colorectal cancer 2B91 Approved [48]
Sunitinib DMCBJSR Gastrointestinal cancer 2C11 Approved [49]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [50]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [32]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [51]
Cabozantinib DMIYDT4 Thyroid cancer 2D10 Approved [52]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [53]
Lenvatinib DMB1IU4 Thyroid cancer 2D10 Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting DNA-dependent protein kinase catalytic (PRKDC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
M3814 DMK2L38 Locally advanced rectal cancer 2B92 Phase 1/2 [45]
AZD7648 DMD9Y5T Solid tumour/cancer 2A00-2F9Z Phase 1/2 [55]
M9831 DM59TI2 Solid tumour/cancer 2A00-2F9Z Phase 1 [45]
LY-292223 DML36ZE Discovery agent N.A. Investigative [56]
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 Discovery agent N.A. Investigative [57]
PIK-75 DM9BQTX Discovery agent N.A. Investigative [58]
KU-0060648 DMQWS6U Discovery agent N.A. Investigative [10]
Alpha-naphthoflavone DMELOIQ Discovery agent N.A. Investigative [59]
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one DM79ZOV Discovery agent N.A. Investigative [59]
2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one DMAHZR9 Discovery agent N.A. Investigative [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Src (SRC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Chronic myelogenous leukaemia 2A20.0 Approved [32]
Bosutinib DMTI8YE Breast cancer 2C60-2C65 Approved [32]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [35]
Herbimycin A DM6YWBF Solid tumour/cancer 2A00-2F9Z Approved [60]
Al3818 DM3WP0N Alveolar soft part sarcoma 2A60-2C35 Phase 3 [45]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [45]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [61]
KX-01 DMF0NA9 Actinic keratosis EK90.0 Phase 3 [62]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [63]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [64]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting ABL messenger RNA (ABL mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
G-1128 DMHOMFK Chronic myelogenous leukaemia 2A20.0 Discontinued in Phase 2 [65]
PMID24900538C2c DM5PATM Discovery agent N.A. Investigative [66]
PMID21561767C8h DMABZH6 Discovery agent N.A. Investigative [67]
PMID23441572C24 DMG4MLA Discovery agent N.A. Investigative [68]
GNF-5 DMGLIPV Discovery agent N.A. Investigative [69]
Drug(s) Targeting PI3-kinase gamma (PIK3CG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bay 80-6946 DMLOS5R Follicular lymphoma 2A80 Approved [70]
IPI-145 DMWA24P Follicular lymphoma 2A80 Approved [71]
Buparlisib DM1WEHC Breast cancer 2C60-2C65 Phase 3 [2]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [45]
Rigosertib DMOSTXF Myelodysplastic syndrome 2A37 Phase 3 [72]
GDC-0032 DMT4QHD Breast cancer 2C60-2C65 Phase 3 [45]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [73]
SAR245409 DMQM7IL Solid tumour/cancer 2A00-2F9Z Phase 2 [74]
Xl147 DMML7BE Solid tumour/cancer 2A00-2F9Z Phase 2 [74]
SF1126 DML10K3 Head and neck cancer 2D42 Phase 2 [75]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ABL messenger RNA (ABL mRNA) TT6B75U ABL1_HUMAN Inhibitor [1]
DNA-dependent protein kinase catalytic (PRKDC) TTK3PY9 PRKDC_HUMAN Inhibitor [1]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [1]
Hematopoietic cell kinase (HCK) TT42OGM HCK_HUMAN Inhibitor [1]
PI3-kinase beta (PIK3CB) TTTHBCA PK3CB_HUMAN Inhibitor [1]
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Inhibitor [1]
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Inhibitor [1]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [1]
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [1]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [1]

References

1 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
2 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154).
4 The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
5 National Cancer Institute Drug Dictionary (drug id 751594).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967).
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36.
9 Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44.
10 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401.
11 Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-11.
12 Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037.
13 Respiratory formulations and compounds for use therein. US8933228.
14 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same. US9062066.
15 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. US9108950.
16 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors. US9724347.
17 Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
18 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
20 A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
22 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
23 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
24 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
25 National Cancer Institute Drug Dictionary (drug id 452042).
26 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
27 Clinical pipeline report, company report or official report of MedImmune (2011).
28 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
29 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
30 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
31 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
32 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
34 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
35 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
36 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
37 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
38 Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
39 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
40 Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
41 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
42 Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
43 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
44 Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
45 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
46 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
47 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
48 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
49 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
50 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
51 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
52 Clinical pipeline report, company report or official report of Exelixis (2011).
53 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
54 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
55 AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065.
56 Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7.
57 Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46.
58 A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.
59 Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85.
60 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
61 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
62 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
63 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
64 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
65 Pharmaceutical Design And Development: A Molecular Biology Approach, T V Ramabhadran, 2005. Page(219).
66 Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
67 Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
68 Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem. 2013 Apr 11;56(7):3033-47.
69 Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6.
70 BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
71 PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
72 Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
73 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
74 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
75 An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81.